← All trials
NCT04416035
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2020
- Primary completion
- Oct 21, 2021
- Completion date
- Nov 10, 2021
- First posted
- Jun 4, 2020
- Last posted
- Jun 4, 2020
- Enrollment
- 608
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang Teruisi Pharmaceutical Inc.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.